NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.32 +0.03 (+2.33 %) (As of 01/16/2019 05:31 AM ET)Previous Close$1.29Today's Range$1.28 - $1.3452-Week Range$1.00 - $2.92Volume340,500 shsAverage Volume220,630 shsMarket Capitalization$74.50 millionP/E Ratio-1.59Dividend YieldN/ABeta2.29 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Receive INFI News and Ratings via Email Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INFI Previous Symbol CUSIP45665G30 Webwww.infi.com Phone617-453-1000Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68Price-To-Earnings Trailing P/E Ratio-1.59 Forward P/E Ratio-5.74 P/E GrowthN/A Sales & Book Value Annual Sales$6 million Price / Sales12.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book1.40Profitability EPS (Most Recent Fiscal Year)($0.83) Net Income$-41,830,000.00 Net MarginsN/A Return on Equity-20.82% Return on Assets-18.24%Miscellaneous Employees22 Outstanding Shares56,870,000Market Cap$74.50 million OptionableOptionable Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions What is Infinity Pharmaceuticals' stock symbol? Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI." How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals Inc. (NASDAQ:INFI) posted its quarterly earnings results on Monday, November, 5th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.37. The biotechnology company had revenue of $22 million for the quarter. View Infinity Pharmaceuticals' Earnings History. When is Infinity Pharmaceuticals' next earnings date? Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Infinity Pharmaceuticals. What price target have analysts set for INFI? 5 brokerages have issued twelve-month price objectives for Infinity Pharmaceuticals' stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 165.2% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals. What is the consensus analysts' recommendation for Infinity Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Infinity Pharmaceuticals. Has Infinity Pharmaceuticals been receiving favorable news coverage? Headlines about INFI stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days. Are investors shorting Infinity Pharmaceuticals? Infinity Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 826,500 shares, a drop of 35.5% from the December 14th total of 1,280,905 shares. Based on an average trading volume of 471,964 shares, the short-interest ratio is currently 1.8 days. Approximately 1.5% of the company's shares are sold short. View Infinity Pharmaceuticals' Current Options Chain. Who are some of Infinity Pharmaceuticals' key competitors? Some companies that are related to Infinity Pharmaceuticals include Minerva Neurosciences (NERV), Neptune Wellness Solutions (NEPT), Achillion Pharmaceuticals (ACHN), BioDelivery Sciences International (BDSI), Albireo Pharma (ALBO), Verrica Pharmaceuticals (VRCA), Intec Pharma (NTEC), Aclaris Therapeutics (ACRS), Kadmon (KDMN), Verastem (VSTM), Savara (SVRA), Tyme Technologies (TYME), Marker Therapeutics (MRKR), Catalyst Pharmaceuticals (CPRX) and Seres Therapeutics (MCRB). Who are Infinity Pharmaceuticals' key executives? Infinity Pharmaceuticals' management team includes the folowing people: Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)Dr. Lawrence E. Bloch, Pres & Treasurer (Age 52)Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 51)Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 39)Ms. Melissa Hackel, VP of Fin. How do I buy shares of Infinity Pharmaceuticals? Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Infinity Pharmaceuticals' stock price today? One share of INFI stock can currently be purchased for approximately $1.32. How big of a company is Infinity Pharmaceuticals? Infinity Pharmaceuticals has a market capitalization of $74.50 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe. What is Infinity Pharmaceuticals' official website? The official website for Infinity Pharmaceuticals is http://www.infi.com. How can I contact Infinity Pharmaceuticals? Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected] MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 290 (Vote Outperform)Underperform Votes: 338 (Vote Underperform)Total Votes: 628MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?